AZTherapies, Inc., is a privately held biotechnology drug development company founded in 2011 and headquartered in Boston, Massachusetts. We are innovating the discovery, development and commercialization of a combination drug regimen for Alzheimer’s disease. Alzheimer’s disease is an irreversible neurodegenerative disease affecting over 5 million individuals in the U.S. and 35 million worldwide. With no cure or viable clinical treatment option, patients continue to rely on inadequate therapies. Disease symptoms include mental debilitation, memory loss and confusion to the point of incoherence, all resulting in the inability to care for oneself, increased healthcare cost and family reliance and suffering. At AZTherapies, we are developing products to fundamentally change the therapeutic approach for this tragic and immense unmet medical need. Our lead product candidate is a drug combination therapy with an exceptional safety profile aimed at slowing down or preventing two major triggers of Alzheimer’s, modifying the course of disease progression early in the disease state. We believe that our novel approach, now in Phase III, will result in providing patients with extended normal cognition and function and improved quality of life and disease management, at the earliest point of interception and before manifestation of the worst disease symptoms.